3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy

Figure 1 Change of liver volume during long-term oral nucleos(t)ide analogues therapy. A: The overall change of liver volume from treatment initiation to second-year follow-up. Liver volume was 993.8 mL ± 242.8 mL at treatment initiation and 1108.1 mL ± 263.3 mL at follow-up. There was 114.3 mL ± 167.8 mL (12.9% ± 17.9%) of volume increase during the two years of treatment period. Compared to the estimated standard liver volume (SLV), as described by Yu et al[14]. which was 1436.0 mL ± 170.2 mL (shaded in gray), measured baseline liver volume in this study was 70.8% and follow-up volume was improved to 78.0% of estimated SLV; B: Comparison of changes of liver volume according to the presence of decompensation at treatment initiation. LC: Liver cirrhosis; F/U: Follow-up.

Figure 2 Representative 3-dimentional reconstruction images in patients with (A) compensated liver cirrhosis and (B) decompensated liver cirrhosis. Among 6 images for each patient, upper images are baseline (pre-NUCs therapy) images and lower images are follow-up (post-NUCs therapy) images in different views (anterior, anteroinferomedial, and posteroinferomedial). NUCs: Nucleos(t)ide analogues.